X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.biospectrumasia.com/news/25/24060/maiweijian-becomes-first-approved-biosimilar-of-denosumab-120mg-in-china.html
https://www.prnewswire.com/news-releases/maiweijian-first-approved-biosimilar-of-denosumab-120mg-in-china-302110441.html
https://endpts.com/sandoz-wins-fda-approval-for-first-two-biosimilars-for-amgens-blockbuster-bone-drug/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761362
https://www.prnewswire.com/news-releases/mabwell-publishes-the-phase-iii-study-results-on-its-denosumab-biosimilar-mw032-in-the-journal-jama-oncology-302067161.html
https://www.fiercepharma.com/pharma/fda-slaps-boxed-warning-amgens-osteoporosis-drug-prolia
https://www.globenewswire.com/news-release/2023/05/25/2675804/0/en/Sandoz-Marketing-Authorization-Applications-for-proposed-biosimilar-denosumab-accepted-by-EMA.html
https://www.prnewswire.com/news-releases/new-data-from-amgens-prolia-denosumab-demonstrates-significant-reduction-in-osteoporotic-fracture-risk-compared-to-alendronate-301818134.html
https://www.fiercepharma.com/pharma/amgen-sues-novartis-sandoz-over-21-alleged-patent-infringements-bone-meds-prolia-and-xgeva
https://endpts.com/amgens-denosumab-shows-promise-in-small-nih-funded-rare-bone-disease-study/
https://www.prnewswire.com/news-releases/the-worlds-second-approved-biosimilars-of-denosumab-mailishu-301787986.html
https://www.globenewswire.com/news-release/2023/02/06/2601765/0/en/Sandoz-Biologics-License-Application-for-proposed-biosimilar-denosumab-accepted-by-US-FDA.html
https://ir.beigene.com/news/beigene-announces-expansion-of-coverage-on-china-s-national-reimbursement-drug-list/e16c132f-efa8-422d-823a-11b6f5352939/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.prnewswire.com/news-releases/mabwell-bioscience-partners-with-binnopharm-group-to-market-9mw0113-9mw0321-and-9mw0311-in-russia-and-eurasian-economic-union-countries-301706985.html
https://www.fda.gov/safety/medical-product-safety-information/prolia-denosumab-amgen-drug-safety-communication-fda-investigating-risk-severe-hypocalcemia-patients
https://www.globenewswire.com/news-release/2022/09/19/2517949/0/en/Sandoz-announces-further-progress-on-its-biosimilar-pipeline-with-release-of-positive-results-for-denosumab-integrated-Phase-I-III-clinical-trial.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-dksh-enters-pact-to-commercials-alvotech-biosimilars-in-philippines/articleshow/94052406.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.expresspharma.in/lupin-and-dksh-sign-exclusive-licensing-and-supply-agreement-to-market-five-biosimilar-candidates-in-philippines/
https://scrip.pharmaintelligence.informa.com/SC146952/Lupin-Liquidating-Japan-JV-With-Yoshindo-Partners-IRom-For-Denosumab-Biosimilar
https://health.economictimes.indiatimes.com/news/pharma/lupin-irom-pharma-enter-into-licensing-agreement-for-denosumab-biosimilar-in-japan/93770257
https://endpts.com/from-functional-to-emotional-amgens-marketing-for-cancer-bone-med-xgeva-shifts-to-patients-stories/
https://www.prnewswire.com/news-releases/richter-and-hikma-sign-exclusive-commercialisation-and-license-agreement-for-denosumab-in-the-us-a-proposed-biosimilar-referencing-prolia-and-xgeva-301440878.html
https://www.bigmoleculewatch.com/2021/06/14/theramex-announces-license-agreement-for-prolia-biosimilar-in-europe-and-australia/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+goodwinprocter-bigmoleculewatchblog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.pharmiweb.com/press-release/2021-06-10/theramex-uk-ltd-announces-a-license-and-supply-agreement-with-enzene-biosciences-limited-for-the-registration-and-commercialisation-of-denosumab-an
https://www.biospectrumasia.com/news/25/17331/china-makes-new-inclusions-in-national-reimbursement-drug-list.html
https://www.biospectrumasia.com/news/25/17331/china-makes-new-inclusions-in-national-reimbursement-drug-list.html
https://www.fiercebiotech.com/research/could-amgen-s-xgeva-boost-immunotherapy-breast-cancer
https://www.biospace.com/article/releases/beigene-announces-the-approval-of-xgeva-denosumab-in-china-for-the-prevention-of-skeletal-related-events-in-patients-with-bone-metastases-from-solid-tumors-and-in-patients-with-multiple-myeloma/?keywords=pharma+new
https://pipelinereview.com/index.php/2020111176499/Antibodies/First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Henlius-Denosumab-Biosimilar-HLX14.html
https://www.pharmacompass.com/pdf/news/samsung-bioepis-initiates-ph-1-trial-for-sb16-proposed-biosimilar-to-prolia-1608206954.pdf
https://www.europeanpharmaceuticalreview.com/news/132430/common-osteoporosis-treatments-could-reduce-incidence-of-covid-19/
https://www.centerforbiosimilars.com/news/henlius-biotech-gets-nmpa-nod-for-denosumab-biosimilar#:~:text=Shanghai%20Henlius%20Biotech%20said%20its,for%20review%20by%20the%20NMPA.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.amgen.com/media/news-releases/2020/01/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/
https://www.medpagetoday.com/hematologyoncology/myeloma/83854
https://endpts.com/amgen-takes-a-2-7b-stake-in-beigene-gaining-a-prominent-ally-in-china-to-help-seize-a-leading-role-in-cancer-drug-commercialization-and-development/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.fiercepharma.com/pharma/genentech-to-settle-biosimilar-trade-secret-theft-suit-taiwan-s-jhl
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
https://www.fiercepharma.com/pharma/consumer-watchdog-petitions-fda-for-black-box-warning-amgen-s-prolia
https://www.fiercepharma.com/marketing/amgen-adds-xgeva-to-oncology-related-drugs-tv-focusing-cancer-patients-bone-metastases
Market Place
Share 
